Bell State Bank & Trust held its position in Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The firm owned 2,507 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bell State Bank & Trust’s holdings in Gilead Sciences were worth $209,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock worth $2,220,410,000 after buying an additional 1,023,299 shares during the last quarter. Temasek Holdings Private Ltd raised its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the last quarter. Parnassus Investments CA raised its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Gilead Sciences during the second quarter worth $427,750,000. 77.94% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Inc. (NASDAQ:GILD) opened at 75.24 on Friday. Gilead Sciences Inc. has a 52 week low of $74.92 and a 52 week high of $111.11. The firm has a market cap of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10. The firm’s 50-day moving average price is $78.95 and its 200 day moving average price is $85.05.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same period last year, the firm posted $3.15 EPS. The business’s revenue was down 5.7% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.
A number of research firms have recently issued reports on GILD. Jefferies Group lifted their price objective on shares of Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday. Piper Jaffray Cos. reiterated a “buy” rating and issued a $108.00 price objective on shares of Gilead Sciences in a report on Monday, August 15th. Morgan Stanley reiterated a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 15th. Berenberg Bank began coverage on shares of Gilead Sciences in a report on Thursday, September 22nd. They issued a “buy” rating on the stock. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Sunday, July 10th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $104.71.
In related news, Director Kevin E. Lofton sold 3,500 shares of Gilead Sciences stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total value of $286,895.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the sale, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.